Please login to the form below
Saizen
This page shows the latest Saizen news and features for those working in and with pharma, biotech and healthcare.
Merck completes €15m Spanish biotech facility expansion
The Tres Cantos plant is Merck's main site for the production of active substances in its fertility treatment Gonal-f and endocrine and metabolic disorders treatment Saizen, for which global
Latest news
-
Sales down at Merck Serono on Rebif pressure
Among its other products, sales of Merck Serono's fertility treatment Gonal-f (follitropin alfa) slipped fractionally to 137m while growth hormone Saizen (somatropin) brought in 61m, in line with one
-
Merck KGaA to meet 2014 financial targets one year early
This performance helped offset declines for other key brands, such as fertility treatment Gonal-f (follitropin alfa) and growth hormone product Saizen (somatropin), down 4 and 8 per cent to 145m
-
Merck Serono to invest €150m in China R&D
The Swiss-based company's key products Erbitux (cancer), Rebif (multiple sclerosis), Gobal-f (infertility), Saizen (endocrine and metabolic disorders) and Concor and Euthyrox (cardiometabolic diseases) are already available in the
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Sanofi's frexalimab shows promise in relapsing forms of MS
- How an AI algorithm might save your life
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Seqera Labs and Genomics England partner to progress genomic research
- Whitepaper: Closing the gap with compelling healthcare communications
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Supporting the most vulnerable: why pharma should get behind the NHS’ healthcare equity campaign
- Healing the Healers
- The (inevitable) digital transformation of Medical Affairs
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
No results were found
PMHub
Thrive Agency
We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...
Latest intelligence
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
- The (inevitable) digital transformation of Medical Affairs
- It’s not a question of ‘if,’ it’s a question of ‘when.’...
